MediGene AG has initiated
a clinical Phase I/II trial of the drug candidate NV1020 for the treatment
of liver metastases developing from colorectal cancer. NV1020 is a
herpes simplex virus, genetically modified for the specific destruction of
tumor cells without harming healthy tissue.
Sangart has initiated
a Phase II clinical trial involving MP4 (Hemospan), a hemoglobin-based oxygen
carrier designed to serve as an alternative for blood transfusions.
Corautus Genetics has
begun its Phase IIb clinical trial to evaluate the safety and efficacy of
Vascular Endothelial Growth Factor-2 (VEGF-2) for the treatment of severe
has completed enrolling 240 patients in the company's multicenter, Phase III
STRIDE-2 (Sitaxsentan To Relieve ImpaireD Exercise) trial to evaluate the
safety and efficacy of sitaxsentan (Thelin) in patients with pulmonary arterial
Genentech and OSI Pharmaceuticals
have initiated a Phase IIIB clinical study of the investigational therapy
erlotinib HCl (Tarceva) in patients with second- and third-line non-small
cell lung cancer who have previously received chemotherapy.
AstraZeneca is recruiting
patients for a new clinical trial for non-small-cell lung cancer. The INTEREST
(IRESSA Non-small-cell lung cancer Trial Evaluating REsponse and Survival
against Taxotere) trial will evaluate the effectiveness of the oral
anti-cancer agent gefitinib (IRESSA) tablets vs. docetaxel (Taxotere) in patients
with locally advanced or metastatic non-small-cell lung cancer who have
previously received platinum-based chemotherapy.
has received a Special Protocol Assessment from the FDA for a pivotal Phase
III clinical trial to evaluate Glufosfamide in patients with metastatic
pancreatic cancer refractory to first-line treatment.